presentation about oncotyrol (2011)

Tel +43.512.576523

Fax +43.512.576523-303

[email protected] www.oncotyrol.atONCOTYROL – Center for Personalized Cancer Medicine GmbH

6020 Innsbruck/Austria, Karl-Kapferer-Straße 5 / III. Stock

Oncotyrol - Center for Personalized Medicine

Oncotyrol is an

applied research

center for

personalized Cancer

Medicine located in

Oncotyrol – at a Glance

Medicine located in

Innsbruck, Tyrol.

Our goal is to

accelerate the

development and

evaluation of

individualized cancer

therapies, along with

prognostic and

preventive methods.

Oncotyrol – the Goal

Applied Research in personalized cancer medicine bridges the gap between

bench and bedside

Oncotyrol – the Goal

Applied research in personalized cancer medicine produces patents, licences

and products

Foto: Pfaller

Molecular Diagnostics Targeted Therapies

Foto: Rainer

Oncotyrol – the partners

Science:

22 research

groups at 5

universities

International partnership between academia and industry

SMEs:

25 Partners Big Industry:

9 Partners

Oncotyrol - a public-private partnership (PPP)

PPP with the mission to bridge the translational gap in drug discovery

Rapid identification of new biomarkers and potential therapeutic

compounds by means of sophisticated research tools

Complementary competencies and alignment of interests between

academic and industrial partners, enabling new opportunities for early

drug discovery of anti-cancer compounds

International visibility through the participation of distinguished

academic partners, SMEs and global pharma players

Growth of Oncotyrol by means of new partnerships and research projects

(Translational research, Bridge , FP7)

Oncotyrol- historical development

� Formation of

� Proposal for

Oncotyrol�2005

�2006/7

�2008/9

� Launch of

Oncotyrol-

Center for

Personalized

Cancer Medicine

�2010/11

� Establishment of

accompanying

research projects

�Oncotyrol lab

and office

buildings finished

� SFB021:

„Cell

Proliferation

and Cell Death

in Tumors“

bewilligt

� Doctoral

Program in

Oncoscience

� Austrian

Proteomics

Platform (APP)

� Formation of

Biocenter

Innsbruck

� 2nd phase

KMT

�Oncology in

the scientific

focus at MUI

� EU-Program

(FP6 Project

Growthstop)

� First „Clinical

Trial Center“ in

Austria

established at the

MUI

� GEN-AU II

�2003

�2004 � 4 x START

grants at the MUI

Biocenter

� Start GENAU III

� Start

competence

center medicine

Tyrol KMT

�2002

� Preparation for

Oncotyrol 2nd

funding period

and beyond

Oncotyrol – the Location

Oncotyrol is based on the scientific and clinical expertise „Made in Tyrol“, but it extends far

beyond. In fact, its hallmark is international partnership between academia and industry.

Global Player with Tyrolean Roots

economy

health

science

Oncotyrol – the location

�University Hospital (I-MED)

�Biocenter (I-MED)

Oncotyrol in the heart of the campus

�100m

�Pharmacy (LFU)

�Chemistry (LFU)�ONCOTYROL

�New Biocenter

(I-MED + LFU)

Oncotyrol – the location

Lab Building Innrain 66a

Oncotyrol - Budget and Finances

Funding by national and regional bodies

ONCOTYROL – Center for personalized cancer medicine GmbH

Total budget: 24 Million € = 100%

Oncotyrol - Budget and Finances

Oncotyrol Budget 2008 - 2012

50% national and regional funding

45% co-financing by industry

5% academic contribution

Oncotyrol - Management & Organization

International Scientific Strategy Board

Universities

56%

Hospital Holding

21%

Province of Tyrol

23%

Shareholders Oncotyrol GmbH

International Scientific Strategy Board

Area 1

G. Baier

CEO

Bernhard Hofer

CSO

Lukas Huber

Area 2

H. Klocker

Area 3

G. Gastl

Area 4

U. Siebert

Area 5

Z. Trajanoski

Core

Facilities

Center Management

Oncotyrol - Management & Organization

Oncotyrol – R & D

Treatment validation in vitro and in vivo

Technology evaluation in diagnostics, therapy

Immune targeting oftumor cell & stroma

BREAST CANCER, PROSTATE CANCER, LEUKEMIA

ONCOTYROL CENTER FOR PERSONALIZED CANCER MEDICINE

in vitro and in vivo in diagnostics, therapy & prevention

Core Facilities

Area 5 Bioinformatics & systems biology

Area 1

Tumor cell biology& anti-tumor immunity

Area 2

Bioanalytics & diagnostics

Area 3

Biomarker-guideddiagnosis, therapy& prevention

Area 4

HTA &health economics,decision modeling

tumor cell & stroma

Oncotyrol – Research

Problem: tumor manipulates the immune system

by upregulating of „hand brake“ gene in T cells

Approach: Downregulation of „hand brake“ gene

in T cells outside of the body. Activated T cells are

Prof. Baier: Activation of T cells against the tumor

in T cells outside of the body. Activated T cells are

given back into the patient

Results: Patents in preparation,

Publication in Science Signaling

Sci Signal. 2009 Jun 23;2(76):ra30.

Gruber T, Hermann-Kleiter N, Hinterleitner R, Fresser F, Schneider R, Gastl G, Penninger JM, Baier G.


Problem: Immune reaction to tumor often

insufficient

Approach: dendritic cells of the patient are

cultivated outside the body, loaded with

tumor antigens and then given back. They activate

Prof. Romani / Thurnher: Therapeutic Vaccination

tumor antigens and then given back. They activate

T cells and trigger a tumor specific immune

response

Results: Successful and well-tolerated vaccinations

of tumor patients, many papers in high-ranking

journals, patent in preparation

Blood, Nov. 2009, Vol. 114, No. 20, pp. 4422-4431

Journal of Investigative Dermatology, 130:755-762, 2010

J Immunother. 2010 Feb-Mar; 33(2):115-25

Immunological Reviews 2010; 234(1):120-41


Problem: What will new technologies cost

and what benefit for the patient and society

will be achieved?

Prof. U. Siebert: Early Health Technology Assessment

Approach: Early Health Technology

Assessment (HTA) helps to direct research into

themost promising directions

Results: International Guidelines for Early HTA in

Personalized cancer Medicine are established


2009: Johann Kern discovers mechanism

for resistence development in tumors

against Bortezomib

Blood, 2009 Oct 29;114(18):3960-7. Epub 2009 Aug 27.

GRP-78 secreted by tumor cells blocks the antiangio-

Sanofi Aventis Prizes for Oncotyrol Researchers

genic activity of bortezomib.

2010: Georg Grünbacher describes

subtypes of dendritic cells that are well

suited for tumor immune therapy

Blood, 12 November 2009, Vol. 114, No. 20, pp. 4422-4431.

CD56+ human blood dendritic cells effectively promote

TH1-type T cell responses

Structures for flexible management of childcare

New Project Onkokids – scientific career and

family committment

Structures for flexible management of childcare

Build-up of a baby sitter pool

Platform „Oncokids“: information, consultation, recruitment

„Oncokids on holidays“: for the first time in summer 2011

Oncotyrol – would you like to collaborate?

Research collaboration. From time-to-time calls for new projects on

Oncotyrol website

Contract research for companies. Outsourcing of research to Oncotyrol

research groups. Services from small research contract us up to large research groups. Services from small research contract us up to large

international consortia (EU projects)

Networking activities. Oncotyrol is interested in projects supporting

international exchange of scientific staff, training workshops, summer

schools, meetings and conferences.

www.oncotyrol.at [email protected]